Full Press Release Details
BridgeBio Pharma's Origin Biosciences Announces FDA Approval Of NULIBRY (fosdenopterin) For The Treatment Of Patients With MoCD Type A.
BBIO
BridgeBio Pharma's Origin Biosciences Announces FDA Approval Of NULIBRY (fosdenopterin) For The Treatment Of Patients With MoCD Type A
Key Takeaway: BridgeBio Pharma's Origin Biosciences Announces FDA Approval Of NULIBRY (fosdenopterin) For The Treatment Of Patients With MoCD Type A
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis